Infectious Diseases Caused by Bacteria and Viruses and the Challenge of Antibiotic Resistance
Main Article Content
Keywords
antibiotics, antimicrobial resistance, vaccine optimization, infectious disease prevention
Abstract
The types of infectious diseases and the number of patients have increased significantly, posing a serious threat to global medical health. In particular, the rise in antibiotic resistance is making bacterial infections more difficult to treat. It is preci sely because of the abuse of antibiotics that bacteria have rapidly developed drug resistance, especially in the case of multidrug -resistant strains, that traditional antibiotic therapy is gradually becoming ineffective. In addition, the rapid mutation of the virus also brings challenges to vaccine development. Taking SARS-CoV-2 as an example, its mutation reduces the effectiveness of the vaccine and increases the complexity of prevention and control. Bacteria and viruses have significant differences in structure and metabolism, which determine their respective treatment methods. Bacteria can be treated with antibiotics, while viruses must rely on vaccines and antiviral drugs to control them. Therefore, scientists are trying to address these challenges by studying bacterial resistance mechanisms, optimizing the composition of HPV vaccines, analyzing the impact of SARS -CoV-2 mutations, and exploring alternative treatments to antibiotics.
References
- [1] S. E. Luria and M. Delbrück, “Mutations of bacteria from virus sensitivity to virus resistance,” Genetics, vol. 28, pp. 491-511, Nov. 1943
- [2] S. H. E. Kaufmann, A. Dorhoi, R. S. Hotchkiss, and R. Bartenschlager, “Host -directed therapies for bacterial and viral infections,” Nature Reviews Drug Discovery, vol. 17, no. 1, pp. 35-56, Jan. 2018, doi: 10.1038/nrd.2017.162.
- [3] R. A. Fisher, B. Gollan, and S. Helaine, “Persistent bacterial infections and persister cells,” Nature Reviews Microbiology, vol. 15, pp. 453-464, Aug. 2017, doi: 10.1038/nrmicro.2017.42
- [4] J. F. Siqueira Jr. and I. N. Rôças, “Clinical implications and microbiology of bacterial persistence after treatment procedures,” Journal of Endodontics, vol. 34, no. 11, pp. 1291 -1301, Nov. 2008, doi: 10.1016/j.joen.2008.07.028
- [5] J. Á. Kaplan, “Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses,” Journal of Dental Research, vol. 89, no. 3, pp. 205-218, 2010.
- [6] H. Niu, J. Gu, and Y. Zhang, “Bacterial persisters: molecular mechanisms and therapeutic development,” Signal Transduction and Targeted Therapy, vol. 9, p. 174, 2024, doi: 10.1038/s41392-024-01866-5
- [7] B. Dadonaite, J. Brown, T. E. McMahon, A. G. Farrell, M. D. Figgins, D. Asarnow, C. Stewart, J. Lee, J. Logue, T. Bedford, B. Murrell, H. Y. Chu, D. Veesler, and J. D. Bloom, “Spike deep mutational scanning helps predict success of SARS -CoV-2 clades,” Natu re, vol. 631, pp. 617 -625, Jul. 2024, doi: 10.1038/s41586-024-07636-1
- [8] R. Wang, H. Huang, C. Yu, X. Li, Y. Wang, and L. Xie, “Current status and future directions for the development of human papillomavirus vaccines,” Frontiers in Immunology, vol. 15, p. 1362770, 2024
- [9] A. Yang, E. Farmer, T. C. Wu, and C. F. Hung, “Perspectives for therapeutic HPV vaccine development,” Journal of Biomedical Science, vol. 23, pp. 1-19, 2016.
- [10] R. Wang, H. Huang, C. Yu, X. Li, Y. Wang, and L. Xie, “Current status and future directions for the development of human papillomavirus vaccines,” Frontiers in Immunology, vol. 15, p. 1362770, Jun. 2024, doi: 10.3389/fimmu.2024.1362770
- [11] W. T. Harvey, A. M. Carabelli, B. Jackson, R. K. Gupta, E. C. Thomson, E. M. Harrison, ... and D. L. Robertson, “SARS-CoV-2 variants, spike mutations, and immune escape,” Nature Reviews Microbiology, vol. 19, no. 7, pp. 409-424, 2021
- [12] A. M. Carabelli, T. P. Peacock, L. G. Thorne, W. T. Harvey, J. Hughes, S. J. Peacock, ... and D. L. Robertson, “SARS-CoV-2 variant biology: immune escape, transmission, and fitness,” Nature Reviews Microbiology, vol. 21, no. 3, pp. 162-177, 2023.
- [13] D. Tian, Y. Sun, J. Zhou, and Q. Ye, “The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape,” Journal of Medical Virology, vol. 94, no. 3, pp. 847-857, 2022.
- [14] A. A. Chis, L. L. Rus, C. Morgovan, A. M. Arseniu, A. Frum, A. L. Vonica -Tincu, F. G. Gligor, M. L. Muresan, and C. M. Dobrea, “Microbial Resistance to Antibiotics and Effective Antibiotherapy,” Biomedicines, vol. 10, no. 5, p. 1121, May 2022, doi: 10.3390/biomedicines10051121
- [15] G. Kapoor, S. Saigal, and A. Elongavan, “Action and resistance mechanisms of antibiotics: A guide for clinicians,” Journal of Anaesthesiology Clinical Pharmacology, vol. 33, no. 3, pp. 300-305, 2017.
- [16] J. Lin, K. Nishino, M. C. Roberts, M. Tolmasky, R. I. Aminov, and L. Zhang, “Mechanisms of antibiotic resistance,” Frontiers in Microbiology, vol. 6, p. 34, 2015.
- [17] D. Tian, Y. Sun, J. Zhou, and Q. Ye, “The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape,” Journal of Medical Virology, vol. 94, no. 3, pp. 847-857, 2022.
- [18] L. Czaplewski, R. Bax, M. Clokie, M. Dawson, H. Fairhead, V. A. Fischetti, ... and J. H. Rex, “Alternatives to antibiotics—a pipeline portfolio review,” The Lancet Infectious Diseases, vol. 16, no. 2, pp. 239-251, 2016
- [19] A. Langdon, N. Crook, and G. Dantas, “The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation,” Genome Medicine, vol. 8, pp. 1-16, 2016.
- [20] S. B. Levy and B. Marshall, “Antibacterial resistance worldwide: causes, challenges, and responses,” Nature Medicine, vol. 10, suppl. 12, pp. S122-S129, 2004.
- [21] J. Wise, “Antimicrobial resistance: MPs call on UK government to maximize potential of bacteriophages,” The BMJ, vol. 384, Jan. 2024
- [22] A. O. Olatunji, J. A. Olaboye, C. C. Maha, T. O. Kolawole, and S. Abdul, “Next-Generation Strategies to Combat Antimicrobial Resistance: Integrating Genomics, CRISPR, and Novel Therapeutics for Effective Treatment,” Engineering Science & Technology Journal, vol. 5, no. 7, pp. 2284-2303, 2024.
- [23] R. I. Aminov, “A brief history of the antibiotic era: lessons learned and challenges for the future,” Frontiers in Microbiology, vol. 1, p. 134, 2010.
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.